RVTY — Revvity, Inc. stock price, charts and financials

QT53Revvity, Inc.

Revvity, Inc. (NYSE: RVTY) is a Healthcare company in the Medical - Diagnostics & Research industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
111.39
-3.83-3.32%
RVTYQT53Revvity, Inc.·NYSE
111.39-3.32%
Filing
Down 3.3% — Filed an 8-K material-event report (2026-08-04) — details in the filing.
Medium confidence
TA
Loading chart...
Signal & projected range
QT Score downgradeHistorical pattern — not a prediction
Range still being built for this setupWe don’t yet have a frozen historical track record for qt score downgrade to describe a reliable spread of outcomes. The projected range appears once its backtest is established.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
Snapshot
IndexS&P 500P/E53.04EPS (ttm)2.10Insider Own0.47%Shs Outstand111.56MPerf Week-0.11%
Market Cap12.43BForward P/E19.16EPS next Y5.81Insider Trans-7.80%Shs Float102.14MPerf Month-1.38%
Enterprise Value14.92BPEG5.64EPS next Q-Inst Own-Short Float7.28%Perf Quarter28.76%
Income241.00MP/S4.28EPS this Y149.66%Inst Trans-Short Ratio5.09Perf Half Y4.02%
Sales2.90BP/B1.73EPS next Y10.89%ROA2.01%Short Interest7.43MPerf YTD15.13%
Book/sh64.39P/C14.45EPS next 5Y9.41%ROE3.28%52W High118.30 -5.84%Perf Year26.25%
Cash/sh7.71P/FCF25.41EPS past 3/5Y-22.69% -20.37%ROIC2.89%52W Low81.22 37.15%Perf 3Y-11.66%
Dividend Est.0.28 (0.25%)EV/EBITDA19.30Sales past 3/5Y-4.82% -5.47%Gross Margin51.44%Volatility4.30% 3.47%Perf 5Y-34.54%
Dividend TTM0.28 (0.25%)EV/Sales5.14EPS Y/Y TTM-12.86%Oper. Margin12.41%ATR (14)4.26Perf 10Y103.30%
Dividend Ex-DateOct 23, 2026Quick Ratio1.41Sales Y/Y TTM5.34%Profit Margin8.30%RSI (14)52.30Recom2.48
Dividend Gr. 3/5Y0.00% 0.00%Current Ratio1.72EPS Q/Q4.95%SMA200.04%Beta1.05Target Price110.40
Payout13.37%Debt/Eq0.48Sales Q/Q6.92%SMA504.34%Rel Volume1.66Prev Close115.22
Employees11,000LT Debt/Eq0.40EarningsOct 26SMA20012.36%Avg Volume1.56MPrice111.39
IPO DateJul 06, 1965Option/ShortYes / YesEPS/Sales Surpr.4.29% 1.00%Net Debt/EBITDA3.22Volume2,587,248Change-3.32%
Analyst Ratings
DateActionAnalystRatingTarget
Jul-06-26ReiteratedEvercore ISI GroupOutperform$118$125
Jun-26-26ResumedBernsteinMarket Perform$130$115
May-06-26ReiteratedStifel Nicolaus$110$100
May-06-26ReiteratedRobert W. Baird$125$117
May-04-26ReiteratedRobert W. Baird$129$125
Apr-14-26DowngradeBarclaysOverweightEqual Weight$118$95
Feb-03-26ReiteratedRobert W. Baird$123$129
Feb-03-26ReiteratedCowen & Co.Outperform$120$124
Feb-03-26ReiteratedBarclaysOverweight$115$118
Feb-03-26ReiteratedEvercore ISI GroupOutperform$108$118
Latest News
Aug-04-26
Jul-31-26
Jul-31-2604:05PM
Jul-30-26
Jul-29-26
Jul-28-26
Jul-24-26
Jul-23-26
Jul-22-26
Jul-20-26
Company

Revvity, Inc., founded in 1937 and based in Waltham, Massachusetts, is a global enterprise that develops and delivers a wide array of products, services, and solutions. The company, which changed its name from PerkinElmer, Inc. in April 2023, caters to the diagnostics, life sciences, and applied services sectors worldwide. Its Discovery & Analytical Solutions division provides advanced instrumentation, reagents, informatics, software, subscriptions, and sophisticated detection and imaging technologies. These resources are designed to enable scientists to achieve significant breakthroughs in life sciences research. This segment also offers contract research and specialized laboratory services. Furthermore, it supplies analytical tools and services for assessing environmental health, including air, water, and soil, and delivers solutions to agricultural and food producers. It also serves the industrial market with analytical instrumentation for sectors such as chemical, semiconductor, electronics, energy, lubricants, petrochemicals, and polymers. The Diagnostics segment is dedicated to early detection, offering instruments, reagents, assay platforms, and software for identifying genetic disorders in pregnant individuals and young children, alongside infectious disease testing. Its products facilitate the screening of genetic abnormalities, disorders, and diseases like Down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This division also innovates technologies that support genomic workflows, leveraging protein-coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. Revvity serves a diverse clientele, including pharmaceutical and biotechnology firms, laboratories, academic and research institutions, public health authorities, private healthcare organizations, medical professionals, and government bodies.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
FY 2025
12/28/2025
FY 2024
12/29/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue2,9022,8562,7552,7513,3123,8283,7832,8842,778
Cost of Goods Sold Incl. D&A1,4091,3401,4321,4281,5511,5461,7921,5911,527
Gross Profit1,4941,5161,3231,3221,7612,2821,9911,2931,251
Selling, General and Administrative Excl. Other914945715706758742765698694
Research and Development220216197217222200205189186
Other Operating Expense-1-20000110
Operating Income3613574113997811,3401,020405371
Interest Expense95929699104102506467
Unusual Expense
Non-Operating Income (Expense)042-118-25-34-64-105-46
Net Income Before Taxes2672683161836521,204906237258
Income Taxes2326333139314178920
Consolidated Net Income241242296-118569943728228239
Net Income From Continuing Operations241242283180513889728228237
Net Income241242296-118569943728228239
EPS (Recurring)2.102.082.41-0.954.518.126.532.052.16
EPS (Basic, Before Extraordinaries)2.102.082.41-0.954.518.126.532.052.16
EPS (Diluted)2.102.082.41-0.954.508.086.492.042.14
EBITDA7736638407141,1831,6171,203515505
Other After Tax Adjustments
Stock Option Compensation Expense
Price To Earnings Ratio53.0446.5146.4731.1524.8722.0947.5836.69
Price To Sales Ratio4.303.835.004.975.336.094.253.743.14
Gross Margin51.4853.0848.0248.0653.1759.6152.6344.8345.03
Operating Margin12.4412.5014.9214.5023.5835.0126.9614.0413.35
Net Margin8.308.4710.74-4.2917.1824.6319.247.918.60
Shares Outstanding112113123125126116112111111
Market Capitalization12,47610,93313,77513,66417,66823,32316,07210,7788,719
Operating Lease Expense
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$123.07$111.54$100.00$88.47$76.94 Close Price0.00M1.17M2.34M3.50M4.67MUSD Trades VolumeAugSepOctNovDec2026FebMarAprMayJunJulAug
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Gonzales AnitaVice President and CAOJul 20 '26Sale109.48859,3067,201Jul 22
Gonzales AnitaVice President and CAOApr 20 '26Sale92.80807,4247,319Apr 22
Victor MiriamePlease See RemarksFeb 24 '26Option Exercise95.743,724356,53619,984Feb 26
Victor MiriamePlease See RemarksFeb 24 '26Sale97.131,862180,85618,122Feb 26
McMurry-Heath MichelleDirectorFeb 23 '26Sale97.2660058,3564,233Feb 25
Goldberg Joel SPlease See RemarksFeb 05 '26Sale100.2112,7171,274,35743,247Feb 06
Singh Prahlad R.Please See RemarksFeb 05 '26Option Exercise92.0925,5252,350,597145,738Feb 06
Singh Prahlad R.Please See RemarksFeb 05 '26Sale100.2125,5252,557,859120,213Feb 06
Goldberg Joel SPlease See RemarksFeb 05 '26Option Exercise92.0912,7171,171,10955,964Feb 06
Vohra Tajinder SPlease See RemarksFeb 02 '26Option Exercise92.0911,5121,060,14016,198Feb 04
Vohra Tajinder SPlease See RemarksFeb 02 '26Sale104.505,756601,50210,442Feb 04
MICHAS ALEXIS PDirectorAug 27 '25Sale89.0150044,5057,270Aug 28
McMurry-Heath MichelleDirectorMay 29 '25Sale92.1760055,2994,833May 30
McMurry-Heath MichelleDirectorFeb 06 '25Sale119.491,970235,3953,021Feb 07
Goldberg Joel SPlease See RemarksJan 30 '25Sale126.7315,1701,922,51333,400Jan 31
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.